Alnylam Pharmaceuticals is seeing a boost in its stock price as investors react positively to recent developments and market conditions.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) is rising today, gaining 2.67% to close at CA$225.77. The company is benefiting from a favorable environment for healthcare stocks, especially those with strong fundamentals and innovative treatments.
Investor takeaway: Investors are encouraged by Alnylam's robust pipeline of RNA interference therapies and its recent initiatives aimed at increasing awareness of its products, which could lead to higher demand and revenues.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$29.40B
P/E
38.3x
52W high
$495.55
52W low
$197.81
1W change
-13.89%
Beta
0.30
Analyst Price Targets
Based on 29 analysts covering ALNY · as of Oct 5, 2026
Wall Street analysts forecast ALNY stock price to rise 68.8% over the next 12 months.
Consensus
Buy4.31 / 5.00
Avg. Target
C$371.12
+68.8% Upside
Current Price
C$219.89
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
45.8%
Annualized
90-Day Vol
71.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$183.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$207.18 | C$176.90 – C$242.65 |
| 60 trading days | C$195.21 | C$156.12 – C$244.10 |
| 90 trading days | C$183.93 | C$139.89 – C$241.84 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Market Cap: $29.4 Billion
Alnylam's substantial market cap reflects investor confidence in its innovative approach to treating rare diseases, supported by a strong portfolio of approved therapies.
Bull case
Alnylam's solid financial position, with a market cap of about $29.4 billion and a profit margin of 16.13%, sets it up well for future growth. The company's focus on RNAi therapeutics has generated significant cash flow, and its expanding drug pipeline promises new revenue opportunities.
Bear case
Despite today's gains, Alnylam faces challenges like pricing pressures and competition in the biotech space. Any setbacks in drug approvals or market acceptance could affect future performance and investor sentiment.
Advertisement
Positive Market Sentiment
Alnylam's stock rise today can be attributed to a broader positive sentiment in the healthcare sector. With global bond markets stabilizing and a focus on financially solid healthcare leaders, investors are increasingly drawn to companies like Alnylam that demonstrate strong cash generation and innovative products.
Innovative Initiatives
The recent launch of the 'Play by Play' initiative, which aims to raise awareness about the symptoms of transthyretin-mediated amyloidosis (ATTR-CM), is also contributing to Alnylam's positive momentum. By engaging former athletes to share their stories, the company is positioning itself as a leader in patient education and advocacy, potentially driving greater demand for its treatments.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
